Tuesday, October 28, 2014
Wednesday, October 29, 2014
Tuesday, October 28, 2014
| 7:45 am – 5:30 pm | Registration |
| 7:45 am – 8:45 am | Pipeline Café |
| 8:45 am – 9:55 am | Welcoming Remarks & Opening Plenary Session The New Normal: Funding Models that Will Drive Innovation in the Next Decade Public and private equity has been flowing to commercial and late stage biopharmaceutical companies, but a funding crisis persists for early-stage firms. As public investors and the reconstituted VC community favor later stage enterprises, who will fund start-ups? Is the industry going to be bifurcated into the economic have and have-nots? And, most importantly, what will the new normal be and how will it affect the pace of innovation? Moderator:
Panelists:
|
| 10:00 am – 10:55 am | Key Opinion Leader Session Immuno-oncology Therapies: Dare We Think “Cure”? Recent advances have markedly changed the utility of immune-oncology therapies. Therapies showing activity have included immune checkpoint inhibitors (e.g. anti-CTCL4, anti-PD1 and anti-PDL1), biospecific antibodies (e.g. CD3 and tumor antigen), CAR-T cells (e.g. CD19 chimeric TCR), GM-CSF expressing oncolytic viruses (e.g. T-Vec) and T-cell activators (e.g. agonist antibodies to OX40 or GITR) and antigen specific cancer vaccines. Synergy has been observed in combining agents with differing modes of action. In several clinical studies, long term responses have been maintained off drug, suggesting durable T-cell activation and memory, and/or complete tumor cell killing. The ability to re-repress and/or activate T-cell engagement of tumor cells represents a major advance in cancer treatment, where durable responses in the treatment of late stage patients with melanoma, NSCLC and renal carcinoma have been observed. Here we explore recent developments in this breakthrough cancer therapy field. Moderator:
Panelists:
|
| 10:00 am – 12:00 pm | Partnering Forum |
| 11:00 am – 11:55 am | Business Workshop Intellectual Property: Value Creation Starts Here Intellectual property is the foundation of the value creation of every biotechnology company. How can an early-stage company or an academic innovator best protect their most important asset while still leveraging its value to the fullest? What do you need to know when in-licensing technology from an academic or research institution? What do you need to know before you negotiate with potential collaborators? Moderator:
Panelists:
|
| 11:00 am – 12:00 pm |
Summit Showcase Pitch Doctors:
|
| 12:00 pm – 1:15 pm | Lunch with the Experts Pipeline Café |
| 1:15 pm – 2:10 pm | Key Opinion Leader Session Precision Medicine & The Opportunity for New Therapies and Better Trials The “one size fits all” approach to cancer therapy is rapidly being replaced by precision medicine. Landmark advances in tumor genomics have resulted in new cancer drugs that target specific molecular alterations or cell signaling pathways, yielding unprecedented anti-cancer activity. The National Cancer Institute’s recently launched “exceptional responders” initiative is examining failed clinical trials for patients who responded well to drugs that the bulk of the trial population did not, with the goal of identifying so-called failed drugs that may have value in very specific patient populations. Join our panelists as they explore the rapidly changing scientific, clinical and commercial landscape as precision medicine becomes the new normal. Moderator:
Panelists:
|
| 1:15 pm – 2:15 pm |
Summit Showcase Pitch Doctors:
|
| 1:15 pm – 4:30 pm | Partnering Forum |
| 2:15 pm – 3:10 pm | Business Workshop Collaboration: How to Court Strategic Partners Strategic partnerships between emerging biotech companies and established biopharmaceutical companies are an important source of financial support as well as validation for early-stage companies. Often there is a mismatch between the expectations of emerging companies and what the interests are of the larger potential partner. What do fledgling entrepreneurs need to understand about larger strategic partners to approach them successfully? Moderator:
Panelists:
|
| 2:15 pm – 3:15 pm |
Summit Showcase Pitch Doctors:
|
| 3:15 pm – 3:30 pm | Coffee Break – Sponsored by |
| 3:30 pm – 4:25 pm | Business Workshop Understanding How to Work with a Banker: Raising Your First Professional Round What do entrepreneurs and innovators need to know before seeking investment outside their friends and family? You need to have a good story about your science and the market potential for your asset, but you should also know some of the basics about deal structure before sitting down with a professional financial advisor for the first time. This panel will discuss the key role bankers can play in leading an early-stage company through the process of seeking investment, as well as deal structure basics. Moderator:
Panelists:
|
| 3:30 pm – 4:30 pm |
Summit Showcase 3:30 pm: Merck |
| 4:30 pm – 5:30 pm | Plenary Session From Whence the ‘Next Big Thing’ Pharmaceutical R&D has been suffering from a lack of innovation for years, and more and more big pharma is resolved to look for the next big thing in start-up biotechs or in academic labs. Most major pharmaceutical companies have established partnerships with academic research institutions. How are these collaborations faring? Should we expect more creative approaches to sourcing innovation? What are venture investors doing to support this critical ecosystem? Moderator:
Panelists:
|
| 5:30 pm – 7:00 pm | Pipeline Café Partnering Reception |
Wednesday, October 29, 2014
